These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
26. Vigabatrin-related adverse events for the treatment of epileptic spasms: systematic review and meta-analysis. Biswas A; Yossofzai O; Vincent A; Go C; Widjaja E Expert Rev Neurother; 2020 Dec; 20(12):1315-1324. PubMed ID: 33078964 [No Abstract] [Full Text] [Related]
27. Vigabatrin in the treatment of infantile spasms in tuberous sclerosis: literature review. Hancock E; Osborne JP J Child Neurol; 1999 Feb; 14(2):71-4. PubMed ID: 10073425 [TBL] [Abstract][Full Text] [Related]
28. Vigabatrin retinal toxicity in children with infantile spasms: An observational cohort study. Westall CA; Wright T; Cortese F; Kumarappah A; Snead OC; Buncic JR Neurology; 2014 Dec; 83(24):2262-8. PubMed ID: 25381295 [TBL] [Abstract][Full Text] [Related]
29. [Treatment of infantile spasms with vigabatrin as first-line therapy and in monotherapy: apropos of 70 infants]. Villeneuve N; Soufflet C; Plouin P; Chiron C; Dulac O Arch Pediatr; 1998 Jul; 5(7):731-8. PubMed ID: 9759271 [TBL] [Abstract][Full Text] [Related]
30. [Vigabatrin in the treatment of epilepsy in patients with West syndrome and tuberous sclerosis]. Rotta NT; da Silva AR; Ohlweiler L; Riesgo R Arq Neuropsiquiatr; 2003 Dec; 61(4):988-90. PubMed ID: 14762603 [TBL] [Abstract][Full Text] [Related]
31. Infantile spasms in Down syndrome: good response to a short course of vigabatrin. Nabbout R; Melki I; Gerbaka B; Dulac O; Akatcherian C Epilepsia; 2001 Dec; 42(12):1580-3. PubMed ID: 11879370 [TBL] [Abstract][Full Text] [Related]
32. What is the optimal duration for vigabatrin monotherapy in patients with infantile spasms: 6 months or longer? Desnous B; Lenoir M; Bitton JY; Arbour M; Villeneuve N; Whiting S; Mohammed I; Wirrell EC; Bello-Espinosa L; Ronen GM; Lortie A; Birca A Seizure; 2021 Oct; 91():503-506. PubMed ID: 34371246 [TBL] [Abstract][Full Text] [Related]
33. Vigabatrin therapy implicates neocortical high frequency oscillations in an animal model of infantile spasms. Frost JD; Le JT; Lee CL; Ballester-Rosado C; Hrachovy RA; Swann JW Neurobiol Dis; 2015 Oct; 82():1-11. PubMed ID: 26026423 [TBL] [Abstract][Full Text] [Related]
34. Evidence-based guideline update: medical treatment of infantile spasms. Report of the Guideline Development Subcommittee of the American Academy of Neurology and the Practice Committee of the Child Neurology Society. Go CY; Mackay MT; Weiss SK; Stephens D; Adams-Webber T; Ashwal S; Snead OC; ; Neurology; 2012 Jun; 78(24):1974-80. PubMed ID: 22689735 [TBL] [Abstract][Full Text] [Related]
36. Epilepsy in children with tuberous sclerosis complex: Chance of remission and response to antiepileptic drugs. Overwater IE; Bindels-de Heus K; Rietman AB; Ten Hoopen LW; Vergouwe Y; Moll HA; de Wit MC Epilepsia; 2015 Aug; 56(8):1239-45. PubMed ID: 26046563 [TBL] [Abstract][Full Text] [Related]
37. Efficacy and safety of vigabatrin in Japanese patients with infantile spasms: Primary short-term study and extension study. Ohtsuka Y Epilepsy Behav; 2018 Jan; 78():134-141. PubMed ID: 29190579 [TBL] [Abstract][Full Text] [Related]
38. Fifteen years of real-world data on the use of vigabatrin in individuals with infantile epileptic spasms syndrome. Kuchenbuch M; Lo Barco T; Chemaly N; Chiron C; Nabbout R Epilepsia; 2024 Feb; 65(2):430-444. PubMed ID: 37872396 [TBL] [Abstract][Full Text] [Related]
39. A risk-benefit assessment of treatments for infantile spasms. Nabbout R Drug Saf; 2001; 24(11):813-28. PubMed ID: 11665869 [TBL] [Abstract][Full Text] [Related]
40. Efficacy and safety of vigabatrin in patients with tuberous sclerosis complex and infantile epileptic spasm syndrome: a systematic review. Prezioso G; Chiarelli F; Matricardi S Expert Rev Neurother; 2023; 23(7):661-671. PubMed ID: 37243682 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]